Level Biotechnology Inc. (TPEX:3118)
Taiwan · Delayed Price · Currency is TWD 33.50
+0.10 (0.30%)
Mar 24, 2026, 1:30 PM CST
Level Biotechnology Market Cap
Level Biotechnology has a market cap or net worth of 1.09 billion as of March 24, 2026. Its market cap has increased by 1.21% in one year.
Market Cap
1.09B
Enterprise Value
884.81M
Revenue
736.59M
Ranking
n/a
PE Ratio
13.73
Stock Price
33.50
Market Cap Chart
Since November 3, 2004, Level Biotechnology's market cap has increased from 249.68M to 1.09B, an increase of 335.42%. That is a compound annual growth rate of 7.12%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 24, 2026 | 1.09B | 1.52% |
| Dec 31, 2025 | 1.07B | 3.13% |
| Dec 31, 2024 | 1.04B | 5.09% |
| Dec 29, 2023 | 988.19M | 10.13% |
| Dec 30, 2022 | 897.32M | -7.68% |
| Dec 30, 2021 | 971.96M | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Great Novel Therapeutics Biotech & Medicals | 1.34B |
| Meribank Biotech | 1.26B |
| Enimmune | 1.24B |
| Lukas Biomedical | 1.11B |
| GeneReach Biotechnology | 1.09B |
| Holy Stone Healthcare | 1.03B |
| TCI GENE | 965.74M |
| Taiwan Advance Bio-Pharmaceutical | 936.00M |